Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 9:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 80 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo + Methotrexate (MTX) Clear all
Terminated Phase 2 Interventional

Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma

NCT02043587
View directory record Official record
Conditions
Acute Lymphocytic Leukemia, Adult Lymphoblastic Lymphoma
Interventions
DNR, VCR, PEG-asp, CTX, Prednisone, Liposomal AraC, MTX, LCV, AraC, Etoposide, Dasatinib, Rituximab, Hydrocortisone
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 60 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
4
States / cities
La Jolla, California • Los Angeles, California • Sacramento, California + 1 more
Source: ClinicalTrials.gov public record
Updated May 1, 2022 · Synced Sep 28, 2026, 9:16 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid Arthritis

NCT01142726
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept, Methotrexate, Abatacept placebo, Methotrexate placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
15
States / cities
Huntsville, Alabama • Hot Springs, Arkansas • Sarasota, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2016 · Synced Sep 28, 2026, 9:16 PM EDT
Terminated Phase 2Phase 3 Interventional

Trial With HuMax-CD4 in Participants With Rheumatoid Arthritis (RA) Failing Treatment With Methotrexate (MTX) and a TNF-alpha Blocker

NCT00042406
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Humax-CD4, Placebo
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
50
States / cities
Montgomery, Alabama • Long Beach, California • Rancho Cucamonga, California + 45 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Sep 28, 2026, 9:16 PM EDT
Completed Phase 4 Interventional Results available

Methotrexate Withdrawal Study of Tofacitinib Modified Release Formulation in Subjects With Rheumatoid Arthritis

NCT02831855
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
CP-690,550, Methotrexate, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
694 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
59
States / cities
Huntsville, Alabama • Gilbert, Arizona • Peoria, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Sep 28, 2026, 9:16 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis

NCT00195663
View directory record Official record
Conditions
Early Rheumatoid Arthritis
Interventions
Adalimumab, Methotrexate, Adalimumab placebo, Methotrexate placebo
Biological · Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older
Enrollment
799 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2012
U.S. locations
31
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2013 · Synced Sep 28, 2026, 9:16 PM EDT
Terminated Phase 2 Interventional Results available

Natalizumab in the Treatment of Rheumatoid Arthritis in Subjects Receiving Methotrexate

NCT00083759
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
natalizumab, placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 75 Years
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
10
States / cities
Birmingham, Alabama • Tucson, Arizona • Escondido, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2016 · Synced Sep 28, 2026, 9:16 PM EDT
Completed Phase 3 Interventional Results available

A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis

NCT01521923
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Certolizumab Pegol + Methotrexate (MTX), Placebo + Methotrexate (MTX)
Biological
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
70
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 63 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 28, 2026, 9:16 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis

NCT01900431
View directory record Official record
Conditions
Uveitis
Interventions
Sarilumab, Prednisone, Methotrexate, Folic/folinic acid, Placebo (for Sarilumab)
Drug · Other
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
5
States / cities
Worcester, Massachusetts • Omaha, Nebraska • Slingerlands, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Sep 28, 2026, 9:16 PM EDT
Completed Phase 3 Interventional Results available

A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate

NCT02706873
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo to Upadacitinib, Methotrexate, Placebo to Methotrexate, Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
1,002 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
32
States / cities
La Mesa, California • Palm Desert, California • Daytona Beach, Florida + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Sep 28, 2026, 9:16 PM EDT
Completed Phase 2 Interventional

A Study of P38 Inhibitor (4) in Patients With Active Rheumatoid Arthritis (RA) on Stable Methotrexate Therapy

NCT00316771
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
P38 Inhibitor (4) 150mg, P38 Inhibitor (4) 25mg, P38 Inhibitor (4) 300mg, P38 Inhibitor (4) 50mg, P38 Inhibitor (4) 75mg, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
48
States / cities
Birmingham, Alabama • Paradise Valley, Arizona • Tucson, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 28, 2026, 9:16 PM EDT
Completed Phase 3 Interventional Results available

Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment

NCT02873936
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Filgotinib, Placebo to match filgotinib, csDMARDs
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
449 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
55
States / cities
Huntsville, Alabama • Gilbert, Arizona • Covina, California + 52 more
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Sep 28, 2026, 9:16 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate

NCT02629159
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo for Adalimumab, Adalimumab, Placebo for Upadacitinib, Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
1,629 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
109
States / cities
Birmingham, Alabama • Mesa, Arizona • Peoria, Arizona + 83 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2025 · Synced Sep 28, 2026, 9:16 PM EDT
Terminated Phase 2 Interventional Results available

Study to Investigate the Safety and Efficacy of Tregalizumab in Subjects (MTX-IR) With Active Rheumatoid Arthritis

NCT01999192
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tregalizumab, Placebo
Drug
Lead sponsor
Biotest
Industry
Eligibility
18 Years to 75 Years
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
8
States / cities
Paradise Valley, Arizona • Springfield, Illinois • Lincoln, Nebraska + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2017 · Synced Sep 28, 2026, 9:16 PM EDT
Completed Phase 4 Interventional Results available

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

NCT01500278
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Certolizumab Pegol (CZP), Adalimumab (ADA), Methotrexate (MTX)
Biological · Drug
Lead sponsor
UCB Pharma SA
Industry
Eligibility
18 Years and older
Enrollment
915 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
62
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Tucson, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2018 · Synced Sep 28, 2026, 9:16 PM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002)

NCT02663622
View directory record Official record
Conditions
Graft Versus Host Disease, Hematopoietic Stem Cell Transplantation, Leukemia
Interventions
Efprezimod alfa, Methotrexate, Tacrolimus, Placebo
Drug
Lead sponsor
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
4
States / cities
Indianapolis, Indiana • Ann Arbor, Michigan • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2024 · Synced Sep 28, 2026, 9:16 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis

NCT00298272
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
IDEC-C2B8 (rituximab), Placebo, Methotrexate, Etanercept, Adalimumab, Methylprednisolone, Folate
Biological · Drug · Dietary Supplement
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
18
States / cities
Huntsville, Alabama • Paradise Valley, Arizona • Palm Desert, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2015 · Synced Sep 28, 2026, 9:16 PM EDT
Completed Phase 3 Interventional Results available

Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy

NCT02886728
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Filgotinib, Placebo to match filgotinib, MTX, Placebo to match MTX
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
1,252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
45
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated May 31, 2021 · Synced Sep 28, 2026, 9:16 PM EDT
Completed Phase 3 Interventional Results available

Study of Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis (JIA)

NCT00048542
View directory record Official record
Conditions
Arthritis, Juvenile Idiopathic
Interventions
Double-Blind Adalimumab/Placebo + MTX, Double-Blind Adalimumab/Placebo, OLE BSA Adalimumab +/- MTX, OLE FD Adalimumab +/- MTX
Biological · Drug
Lead sponsor
Abbott
Industry
Eligibility
4 Years to 17 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • Stanford, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2011 · Synced Sep 28, 2026, 9:16 PM EDT
Completed Phase 3 Interventional Results available

A Study of Tocilizumab and Methotrexate Treatment Strategies (Adding Tocilizumab to Methotrexate Versus Switching to Tocilizumab) in Patients With Active Rheumatoid Arthritis With Inadequate Response to Prior Methotrexate Treatment

NCT00810199
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
tocilizumab [RoActemra/Actemra], methotrexate, placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
556 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
21
States / cities
Santa Monica, California • Upland, California • Whittier, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2014 · Synced Sep 28, 2026, 9:16 PM EDT
Completed Phase 4 Interventional Results available

Study of the Optimal Protocol for Methotrexate and Adalimumab Combination Therapy in Early Rheumatoid Arthritis

NCT00420927
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
adalimumab, methotrexate, placebo
Biological · Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
1,032 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
49
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 45 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2012 · Synced Sep 28, 2026, 9:16 PM EDT
Completed Phase 3 Interventional Results available

An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate Therapy

NCT00973479
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Golimumab, Placebo, methotrexate (MTX)
Drug · Other
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
592 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
9
States / cities
Daytona Beach, Florida • Miami, Florida • Palm Harbor, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2013 · Synced Sep 28, 2026, 9:16 PM EDT
Completed Phase 4 Interventional Results available

Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout

NCT03994731
View directory record Official record
Conditions
Gout
Interventions
Pegloticase, methotrexate, placebo, folic acid, gout flare prophylaxis regimen, fexofenadine, acetaminophen, methylprednisolone
Biological · Drug · Dietary Supplement
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
60
States / cities
Birmingham, Alabama • Anchorage, Alaska • Flagstaff, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Sep 28, 2026, 9:16 PM EDT
Completed Phase 2 Interventional Results available

A Study for Patients With Rheumatoid Arthritis on Methotrexate (MTX) With an Inadequate Response to TNFα Inhibitor Therapy

NCT00689728
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
LY2127399, Placebo
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
19
States / cities
Birmingham, Alabama • Mesa, Arizona • Palm Desert, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Sep 28, 2026, 9:16 PM EDT
Completed Phase 3 Interventional Results available

A Study in Moderate to Severe Rheumatoid Arthritis

NCT01710358
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Adalimumab, Baricitinib, Methotrexate, Adalimumab Placebo, Baricitinib Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
45
States / cities
Glendale, Arizona • Peoria, Arizona • Phoenix, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Sep 28, 2026, 9:16 PM EDT